Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.12M Hold
165,300
0.73% 66
2025
Q4
$4.12M Buy
165,300
+15,304
+10% +$386K 0.73% 66
2025
Q3
$3.82M Buy
149,996
+33,601
+29% +$829K 1.2% 41
2025
Q2
$2.82M Buy
116,395
+23,629
+25% +$551K 0.98% 49
2025
Q1
$2.35M Buy
92,766
+15,691
+20% +$411K 0.99% 49
2024
Q4
$2.04M Buy
77,075
+3,404
+5% +$92.3K 0.85% 46
2024
Q3
$2.13M Buy
73,671
+3,767
+5% +$110K 1.05% 42
2024
Q2
$1.96M Buy
69,904
+1,541
+2% +$42.4K 0.93% 45
2024
Q1
$1.9M Buy
68,363
+27,064
+66% +$751K 0.92% 51
2023
Q4
$1.19M Buy
+41,299
New +$1.25M 0.75% 53

Other funds holding PFE

KKM Financial's PFE Position: Q1 2026 in Review

KKM Financial held its Pfizer (PFE) position steady in Q1 2026 at 165,300 shares worth $4.12M. The position accounts for 0.73% of the portfolio, ranked #66.

KKM Financial first reported a position in PFE in Q4 2023 and has held it in 10 quarters since. 2,936 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • KKM Financial held 165,300 shares of Pfizer worth $4.12M as of Q1 2026.
  • KKM Financial left its Pfizer share count unchanged in Q1 2026.
  • Pfizer made up 0.73% of KKM Financial's portfolio in Q1 2026, its #66 holding.
  • KKM Financial first reported a position in Pfizer in Q4 2023 and has held it in 10 quarters since.
  • 2,936 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on KKM Financial's 13F filing for Q1 2026, filed 15 May 2026.